RxDoctor Payments Data

Azhil Durairaj, MD

Interventional Cardiology · Pasadena, CANPI 1609826973

Payments from drug & device makers

$220,796in general payments, 2019–2025

Across 991 payments — averaging $222.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$148K
  • Abbott$57K
  • Boston Scientific$3K
  • Novartis$1K
  • Amgen$1K
  • Pfizer$1K
  • plus $9K from 48 others

What the payments were for

  • Travel & lodging$10,11626%
  • Food & beverage$28,55973%
  • Education$1380%
  • Entertainment$490%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$220,796 in reported general payments places this provider in the 85th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$378,970
Medicare patients
1,086
Services billed
4,531

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban315$350,047
EntrestoSacubitril/Valsartan177$208,263
JardianceEmpagliflozin149$193,792
Repatha SureclickEvolocumab237$166,667
XareltoRivaroxaban69$68,465
Praluent PenAlirocumab67$40,446
FarxigaDapagliflozin Propanediol47$38,236
MultaqDronedarone Hcl16$36,371
Rosuvastatin Calcium1,051$20,969
Ranolazine ErRanolazine161$20,449
VascepaIcosapent Ethyl28$15,398
OzempicSemaglutide15$15,270
Irbesartan696$13,098
Carvedilol876$7,253
Ezetimibe343$7,173

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,143$350,047315 claims
NovartisEntresto$1,371$208,263177 claims
Boehringer IngelheimJardiance$323$193,792149 claims
Johnson & JohnsonXarelto$293$68,46569 claims
AstraZenecaFarxiga$307$38,23647 claims
Sanofi-aventis U.S. LLCMultaq$106$36,37116 claims
Novo NordiskOzempic$107$15,27015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Pasadena

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →